

Supplementary Table 1. Statistical analysis of reactogenicity data between booster vaccines.

	Total	BBIBP	AZD1222	BNT162b2	mRNA- 1273	Pearson's χ^2	Pair-wise analysis (Fisher's Exact test)						
							1 vs 2	1 vs 3	1 vs 4	2 vs 3	2 vs 4	3 vs 4	
N (%)	224 (100)	57 (100)	55 (100)	54 (100)	58 (100)								
Injection site pain	187 (83.5)	34 (59.6)	46 (83.6)	52 (96.3)	55 (94.8)	< 0.001	0.006	< 0.001	< 0.001	0.052	0.069	1.000	
Swelling	71 (31.7)	2 (3.5)	19 (34.5)	16 (29.6)	34 (58.6)	< 0.001	< 0.001	< 0.001	< 0.001	0.683	0.010	0.002	
Redness	63 (28.1)	6 (13.7)	16 (29.1)	18 (33.3)	23 (39.7)	0.004	0.017	0.005	< 0.001	0.683	0.322	0.558	
Fever	11 (4.9)	0 (0.0)	5 (9.1)	2 (3.7)	4 (6.9)	0.046 ^a	0.026	0.234	0.119	0.438	0.738	0.680	
Headache	120 (53.6)	28 (49.1)	34 (61.8)	20 (37.0)	38 (65.5)	0.011	0.189	0.251	0.091	0.013	0.700	0.004	
Myalgia	148 (66.1)	24 (42.1)	41 (74.5)	38 (70.4)	45 (77.6)	< 0.001	0.001	0.004	< 0.001	0.672	0.826	0.398	
Nausea	37 (16.5)	9 (15.8)	11 (20.0)	7 (13.0)	10 (17.2)	0.796	0.627	0.789	1.000	0.440	0.810	0.604	
Vomiting	6 (2.7)	0 (0.0)	0 (0.0)	2 (3.7)	4 (6.9)	0.029 ^a	N/A	0.234	0.119	0.243	0.119	0.680	
Diarrhoea	32 (14.3)	6 (10.5)	12 (21.8)	4 (7.4)	10 (17.2)	0.127	0.127	0.743	0.420	0.056	0.637	0.155	
Joint pain	53 (23.7)	7 (12.3)	19 (34.5)	7 (13.0)	20 (34.5)	0.002	0.007	1.000	0.008	0.013	1.000	0.009	
Chilling	101 (45.1)	9 (15.8)	32 (58.2)	20 (37.0)	40 (69.0)	< 0.001	< 0.001	0.017	< 0.001	0.035	0.248	0.001	
Dizziness	67 (39.9)	13 (22.8)	17 (30.9)	14 (25.9)	23 (49.7)	0.218	0.396	0.825	0.070	0.672	0.431	0.160	

^a Likelihood Ratio is applied due to expected cell count less than 5 more than 20% of cells

Supplementary Table 2. The value and statistical analysis of GMT (with 95% confidence intervals) of total RBD Ig and anti-RBD IgG, median (with interquartile ranges) of anti-N IgG.

	BBIBP (I)	AZD1222 (II)	BNT162b2 (III)	mRNA-1273 (IV)	Total	Kruskal- Wallis	Pair-wise analysis (Mann Whitney)					
							(I) vs (II)	(I) vs (III)	(I) vs (IV)	(II) vs (III)	(II) vs (IV)	(III) vs (IV)
SARS-CoV-2 total RBD Ig, (U/ml), GMT 95% CI]												
Day 0	46.01 (33.87-62.50)	35.17 (27.32-45.26)	41.67 (31.38-55.32)	27.07 (20.44-35.84)	36.49 (31.72-41.97)	0.033 ^a	1.000	1.000	0.035	1.000	1.000 ^b	0.156
Day 14	1740.00 (1443.81-2096.95)	12259.51 (10333.78-14544.10)	31792.88 (27428.26-36852.03)	51979.58 (43920.69-61516.02)	13650.90 (11269.99-16534.79)	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001 ^b	0.099
Day 28	1294.54 (1084.08-1545.87)	12111.12 (10153.22-14446.57)	21053.33 (18145.07-24427.73)	33519.20 (28228.32-39802.45)	10146.77 (8426.09-12218.84)	< 0.001	< 0.001	< 0.001	< 0.001	0.017	< 0.001 ^b	0.085
SARS-CoV-2 anti-RBD IgG, (BAU/ml), GMT [95% CI]												
Day 0	23.16 (17.83-30.08)	17.55 (14.52-21.23)	26.01 (21.16-31.97)	18.13 (14.78-22.23)	20.85 (18.71-23.23)	0.028 ^a	0.435	1.000	0.609	0.073	1.000 ^b	0.109
Day 14	212.55 (175.84-256.93)	2226.68 (1858.02-2668.49)	4877.73 (4221.82-5635.55)	8901.15 (7471.96-10605.14)	2120.51 (1723.96-2608.29)	< 0.001	< 0.001	< 0.001	< 0.001	0.001	< 0.001 ^b	0.017
Day 28	183.83 (153.94-219.51)	1808.49 (1528.28-2140.07)	3836.95 (3292.30-4471.70)	6846.00 (5867.92-7987.17)	1702.33 (1393.57-2079.51)	< 0.001	< 0.001	< 0.001	< 0.001	0.002	< 0.001 ^b	0.012
SARS-CoV-2 anti-N IgG, (S/C), median [IQR]												
Day 0	0.16 (0.08-0.32)	0.12 (0.05-0.26)	0.15 (0.10-0.36)	0.13 (0.07-0.33)	0.13 (0.07-0.31)	0.251	ns	ns	ns	ns	ns	ns
Day 14	2.78 (1.84-5.30)	0.12 (0.05-0.27)	0.14 (0.09-0.41)	0.14 (0.09-0.37)	0.24 (0.09-1.13)	< 0.001	< 0.001	< 0.001	< 0.001	1.000	1.000	1.000
Day 28	2.89 (1.55-4.87)	0.10 (0.06-0.23)	0.12 (0.08-0.31)	0.12 (0.07-0.31)	0.19 (0.08-1.02)	< 0.001	< 0.001	< 0.001	< 0.001	1.000	1.000 ^b	1.000

^a tested using student's t-test; tests were adjusted by Bonferroni correction for multiple tests.

^b adjusted for age


Supplementary Table 3. The percentage inhibition against wild-type and SARS-CoV-2 variants.

	BBIBP (I)	AZD1222 (II)	BNT162b2 (III)	mRNA-1273 (IV)
sVNT—Wild Type. (GenScript), median (IQR)				
Day 0	20.50 (13.60-32.00)	15.45 (11.20-24.38)	20.15 (8.075-30.55)	7.250 (1.20-17.00)
Day 28	87.55 (72.58-96.63)	97.30 (97.10-97.50)	97.50 (97.30-97.50)	98.30 (98.30-98.40)
sVNT—Alpha. (GenScript), median (IQR)				
Day 0	22.0 (14.4-29.2)	20.6 (15.5-23.6)	23.8 (15.8-27.0)	5.10 (0.075-8.48)
Day 28	75.4 (55.8-92.4)	97.9 (97.5-98.3)	98.1 (97.9-98.3)	98.2 (98.2-98.3)
sVNT—Beta. (GenScript), median (IQR)				
Day 0	8.65 (3.75-23.9)	9.20 (5.35-12.5)	9.20 (5.35-12.5)	13.5 (6.50-18.9)
Day 28	68.7 (44.5-84.6)	96.0 (94.2-96.8)	96.0 (94.2-96.8)	98.0 (97.6-98.2)
sVNT—Delta. (GenScript), median (IQR)				
Day 0	18.4 (14.1-37.8)	14.8 (12.6-21.8)	22.7 (10.2-31.2)	19.1 (9.80-24.0)
Day 28	86.0 (69.6-94.8)	97.5 (97.3-97.6)	97.5 (97.3-97.6)	98.2 (98.2-98.3)
sVNT—Omicron. (GenScript), median (IQR)				
Day 0	6.70 (4.18-8.88)	4.05 (2.45-6.68)	5.50 (1.85 -8.55)	5.35 (3.93-12.7)
Day 28	9.00 (0.00-17.7)	45.3 (26.5-76.2)	53.5 (26.3-70.0)	76.7 (60.6-91.6)


Supplementary Table 4. The IFN- γ CD4+/IFN- γ CD4+ and CD8+ levels

	BBIBP (I)	AZD1222 (II)	BNT162b2 (III)	mRNA-1273 (IV)
IFN-γ CD4+ T-cell (IU/ml), median (IQR)				
Day 0	0.04 (0.00-0.155)	0.05 (0.01-0.22)	0.05 (0.01-0.19)	0.03 (0.01-0.20)
Day 14	0.09 (0.01-0.38)	0.18 (0.53-1.60)	1.12 (0.41-2.22)	0.9 (0.25-1.78)
Day 28	0.14 (0.02-0.25)	0.30 (0.13-0.90)	0.74 (0.20-1.46)	0.77 (0.26-1.83)
IFN-γ CD4+/CD8+ T-cell (IU/ml), median (IQR)				
Day 0	0.06 (0.01-0.198)	0.12 (0.03-0.25)	0.10 (0.02-0.23)	0.11 (0.00-0.31)
Day 14	0.12 (0.05-0.43)	0.88 (0.48-2.32)	2.22 (0.82-2.70)	1.68 (0.39-2.68)
Day 28	0.16 (0.02-0.35)	0.48 (0.29-1.21)	1.02 (0.37-2.40)	1.03 (0.40-2.31)


Supplementary Figure 1. Participant flow chart in the heterologous booster cohorts.




A



B




C



Supplementary Figure 2. Forest plot presents any grade the solicited local and systemic adverse events (AEs) across 7 days post-boost vaccination and the absolute risk differences comparison between BBIBP to AZD1222, BNT162b2, and mRNA1273 in the proportion of participants with 95% confidence intervals.

Alpha



Supplement Figure 3. The neutralizing activities against alpha variant. Each data point is represented of the individual who received a heterologous third booster vaccine, the inactivated vaccine, BBIBP (green), the viral-vector vaccine, AZD1222 (orange), the mRNA vaccine, BNT162b2 (blue), or mRNA-1273 (gold). Lines represent median (IQR). ns indicates no significant difference; $p < 0.01$ (**), $p < 0.001$ (***).